š”š²šš š¦ššŗšŗš®šæš
ā¢ Zydus Lifesciences is focusing on proprietary and differentiated products, with the aim of generating half of its revenue from these products by 2028.
ā¢ The company is also investing heavily in research and development, with 8% of its revenue allocated towards developing new chemical entities, biologics, and differentiated products.
ā¢ Zydus is also expanding its market access for its products through licensing models, such as the recent deal with Sun Pharma for co-marketing Desidustat.